Varenicline for smoking cessation: efficacy, safety, and treatment recommendations
Authors:
- Jon O EbbertJEJon O Ebbert
- Kirk D WyattKWKirk D Wyatt
- J Taylor HaysJHJ Taylor Hays
- Eric W KleeEKEric W Klee
- Richard D HurtRHRichard D Hurt
Open Access
- 1 September 2010
- journal article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. 4, 355-62
Abstract
Peer reviewed article authored by (Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, et al). Read article or submit your manuscript for publishing.Keywords
This publication has 46 references indexed in Scilit:
- Nicotine addiction and nicotinic receptors: lessons from genetically modified miceNature Reviews Neuroscience, 2010
- Adherence to treatment for tobacco dependence: Association with smoking abstinence and predictors of adherenceNicotine & Tobacco Research, 2010
- The Cost-Effectiveness of an Extended Course (12 + 12 Weeks) of Varenicline Compared with Other Available Smoking Cessation Strategies in the United States: An Extension and Update to the BENESCO ModelValue in Health, 2010
- Treating Tobacco Dependence in a Medical SettingCA: A Cancer Journal for Clinicians, 2009
- Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatmentAddiction, 2009
- Varenicline as compared to bupropion in smoking-cessation therapy—Cost–utility results for Sweden 2003Respiratory Medicine, 2008
- Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking CessationA Randomized Controlled TrialJAMA, 2006
- Varenicline: An α4β2 Nicotinic Receptor Partial Agonist for Smoking CessationJournal of Medicinal Chemistry, 2005
- Behavioural and pharmacokinetic studies on nicotine, cytisine and lobelineNeuropharmacology, 1990
- Some studies on cytisine and its methylated derivativesBritish Journal of Pharmacology, 1969